Clinical Trials

An open label, Phase I dose-finding study of BI 754111 in combination with BI 754091 in patients with advanced solid cancers followed by expansion cohorts at the selected dose of the combination in patients with non-small cell lung cancer and other solid tumors


Study ID
Boehringer Ingelheim 1381.2 REFMAL 485

NCT Number
NCT03156114 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0797

Principle Investigator
Dr. Martin Gutierrez

Phase
I

Sponsor
Boehringer Ingelheim


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now